Brown Advisory Inc. Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Brown Advisory Inc. lessened its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 215,320 shares of the medical device company's stock after selling 45,666 shares during the period. Brown Advisory Inc. owned about 0.06% of DexCom worth $16,745,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after purchasing an additional 56,094 shares during the last quarter. Jennison Associates LLC grew its holdings in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Norges Bank acquired a new stake in DexCom in the 4th quarter valued at about $385,367,000. Northern Trust Corp raised its stake in shares of DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after acquiring an additional 753,857 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after purchasing an additional 91,051 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Trading Down 0.8 %

DexCom stock traded down $0.68 during trading hours on Friday, reaching $84.66. The stock had a trading volume of 3,348,982 shares, compared to its average volume of 4,321,123. The company has a fifty day simple moving average of $71.08 and a 200-day simple moving average of $77.17. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26. The stock has a market cap of $33.20 billion, a PE ratio of 59.20, a PEG ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the company earned $0.32 EPS. The company's revenue for the quarter was up 12.5% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on DXCM. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group raised their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Mizuho assumed coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $98.11.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. This trade represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 in the last three months. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.